Stockhead Article: AT1 raising $4m to scale-up Pascal cassette supply

Atomo was recently featured in this article by Stockhead.

“To support anticipated growth in the business, we are pleased to have secured firm commitments from institutional and sophisticated professional investors to raise approximately $3m through the placement and thank them for their support,” managing director John Kelly said.

“This additional capital enables the company to expand commercialisation of Atomo’s own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale-up to support increased demand for supply of Pascal cassettes for Lumos’ FebriDx growth in the US, new “Atomo inside” customers and Atomo’s own products.”